Welcome to our dedicated page for Proassurance Cp SEC filings (Ticker: PRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the financial health of a specialty insurer like ProAssurance can feel daunting—the latest 10-K spans multiple liability segments, reinsurance treaties, and reserve calculations. Investors trying to pinpoint healthcare liability loss ratios or monitor ProAssurance insider trading Form 4 transactions often spend hours scrolling through dense language.
Stock Titan solves this with real-time EDGAR feeds and AI-powered summaries. The moment a filing hits EDGAR—ProAssurance 8-K material events explained instantly—you’ll see a concise plain-English note. Our platform highlights section references inside every ProAssurance annual report 10-K simplified, flags shifts in combined ratios inside each ProAssurance quarterly earnings report 10-Q filing, and streams ProAssurance Form 4 insider transactions real-time so you can act before the market reacts.
Need quick answers? Type natural questions like “understanding ProAssurance SEC documents with AI” or “ProAssurance proxy statement executive compensation” and jump straight to our plain-English notes. Use cases include:
- Comparing reserve development with our ProAssurance earnings report filing analysis
- Monitoring ProAssurance executive stock transactions Form 4 ahead of dividend announcements
- Reviewing claim severity trends via ProAssurance SEC filings explained simply
Whether you’re an equity analyst tracking the Lloyd’s syndicate result or a healthcare CFO verifying coverage ratios, Stock Titan delivers every filing type—10-K, 10-Q, 8-K, S-1, DEF 14A—complete with AI context. Skip the jargon, keep the insight.
ProAssurance (PRA) Q2-25 10-Q highlights: Net premiums earned slipped 3% YoY to $232.4 m, but higher investment income (+6% to $38.9 m) and a 14% drop in loss costs lifted quarterly net income 41% to $21.9 m (diluted EPS $0.42). Six-month revenues fell 5% to $548.8 m and net income declined 20% to $16.1 m (EPS $0.31) after $11.6 m merger-related expenses.
Shareholders’ equity rose 6% since year-end to $1.28 bn as AOCI improved $55.8 m with bond-market recovery. Book value approximates $24–25 per share, near the $25 cash offer in the pending merger with The Doctors Company. The deal, signed 19 Mar 25, gained shareholder approval 24 Jun 25 and early HSR clearance 2 Jul 25; closing targeted 1H-26, pending remaining regulatory consents.
- Combined ratio (est.) improved to ~96.4% from ~98.2%.
- Operating cash flow YTD: –$39.7 m (–$24.5 m PY).
- Investment portfolio $4.38 bn; unrealized loss narrowed to $116.6 m.
- Debt $422.6 m; net leverage ~0.3× equity.
- Sale of Franklin, TN property generated $19.3 m cash and $2.2 m gain.
No new accounting standards adopted; upcoming FASB disclosure rules being evaluated.
Date: August 5, 2025. Event: ProAssurance Corporation (PRA) furnished a news release reporting results of operations for the quarter ended June 30, 2025 as Exhibit 99.1 to this Form 8-K.
Disclosure: The company also updated online disclosure of its entire investment portfolio with holdings through June 30, 2025, available under Quarterly Results in the Financial Information section of its Investor Relations website. The filing states the furnished information is not being "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated. The Form 8-K is signed by Jeffrey P. Lisenby, General Counsel.
ProAssurance Corporation (NYSE: PRA) reported that shareholders overwhelmingly approved all proposals connected with its pending merger with The Doctors Company at a special meeting held on 24 June 2025.
• Merger Agreement adoption: 38,225,337 shares voted FOR, just 363,050 AGAINST and 22,192 ABSTAIN; no broker non-votes were recorded. Support exceeded 99% of votes cast, comfortably surpassing any approval threshold.
• Say-on-Pay (merger-related compensation): 31,191,544 FOR, 7,185,578 AGAINST, 233,457 ABSTAIN—an 81% approval rate on an advisory basis.
• Adjournment proposal: Not required because quorum (≈75.6% of outstanding 51,070,243 shares) was achieved and the merger proposal passed.
Under the Agreement and Plan of Merger signed 19 March 2025, Jackson Acquisition Corporation (a wholly owned subsidiary of The Doctors Company) will merge with and into ProAssurance, making ProAssurance a wholly owned subsidiary of The Doctors Company. Management currently expects closing in the first half of 2026, subject to regulatory clearances and other customary conditions.
The filing reiterates extensive forward-looking risk factors, including regulatory approvals, potential litigation, business disruption, personnel retention and market reactions during the pre-closing period. A related news release (Exhibit 99.1) announcing the vote results was issued the same day.
FAQ
What is the current stock price of Proassurance Cp (PRA)?
What is the market cap of Proassurance Cp (PRA)?
